KDIGO made 12 recommendations for managing diabetes with CKD

Area of Science:

• Nephrology
• Endocrinology
• Internal Medicine
• Clinical Practice Guidelines

Background:

• Diabetes is a leading cause of chronic kidney disease (CKD).
• Effective management of diabetes in CKD patients is crucial to slow disease progression and reduce cardiovascular risk.
• The Kidney Disease: Improving Global Outcomes (KDIGO) organization provides evidence-based guidelines for CKD care.

Purpose of the Study:

• To present a synopsis of the 2020 KDIGO Clinical Practice Guideline for diabetes management in CKD.
• To highlight key recommendations for healthcare providers caring for patients with both diabetes and CKD.
• To facilitate the implementation of best practices in diabetes and CKD management.

Main Methods:

• Review and synthesis of the 2020 KDIGO guideline document.
• Focus on recommendations related to glycemic control, blood pressure management, and pharmacotherapy in CKD patients with diabetes.
• Inclusion of considerations for different stages of CKD and specific patient populations.

Main Results:

• The guideline emphasizes individualized glycemic targets based on patient factors.
• Recommendations include the use of specific pharmacotherapies (e.g., SGLT2 inhibitors, GLP-1 receptor agonists) with demonstrated kidney and cardiovascular benefits.
• Updated guidance on managing hypertension and other comorbidities in the context of diabetes and CKD.

Conclusions:

• The 2020 KDIGO guideline provides comprehensive, evidence-based recommendations for diabetes management in CKD.
• Adherence to these guidelines can improve patient outcomes, including slowing CKD progression and reducing cardiovascular events.
• This synopsis serves as a practical resource for clinicians to integrate the latest recommendations into their practice.